RXO Valuation
Is N9Q undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of N9Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: N9Q (€28.6) is trading below our estimate of fair value (€40.44)
Significantly Below Fair Value: N9Q is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for N9Q?
Key metric: As N9Q is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is N9Q's PS Ratio? | |
|---|---|
| PS Ratio | 1.2x |
| Sales | US$3.86b |
| Market Cap | US$4.97b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | 52x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does N9Q's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.6x | ||
3WB Waberer's International Nyrt | 0.2x | 9.8% | €155.6m |
SIX2 Sixt | 0.8x | 6.3% | €3.0b |
FRA Fraport | 1.1x | 1.3% | €4.8b |
LHA Deutsche Lufthansa | 0.2x | 3.9% | €7.4b |
N9Q RXO | 1.2x | 22.4% | €5.0b |
Price-To-Sales vs Peers: N9Q is expensive based on its Price-To-Sales Ratio (1.2x) compared to the peer average (0.6x).
Price to Sales Ratio vs Industry
How does N9Q's PS Ratio compare vs other companies in the European Transportation Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: N9Q is expensive based on its Price-To-Sales Ratio (1.2x) compared to the European Transportation industry average (0.8x).
Price to Sales Ratio vs Fair Ratio
What is N9Q's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.2x |
| Fair PS Ratio | 1.1x |
Price-To-Sales vs Fair Ratio: N9Q is expensive based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €28.60 | €25.85 -9.6% | 18.8% | €31.16 | €11.33 | n/a | 16 |
| Nov ’25 | €25.80 | €25.79 -0.03% | 15.6% | €30.48 | €14.78 | n/a | 14 |
| Oct ’25 | €24.60 | €24.60 +0.001% | 16.7% | €28.91 | €14.45 | n/a | 13 |
| Sep ’25 | €25.20 | €25.02 -0.7% | 14.0% | €29.16 | €18.22 | n/a | 13 |
| Aug ’25 | €28.60 | €21.98 -23.2% | 20.5% | €29.40 | €12.86 | n/a | 13 |
| Jul ’25 | €23.60 | €19.74 -16.4% | 20.2% | €27.99 | €13.06 | n/a | 13 |
| Jun ’25 | €18.00 | €18.45 +2.5% | 16.4% | €23.15 | €12.04 | n/a | 14 |
| May ’25 | €17.70 | €18.75 +5.9% | 14.5% | €23.36 | €14.01 | n/a | 14 |
| Apr ’25 | €19.50 | €18.56 -4.8% | 14.3% | €23.07 | €14.76 | n/a | 13 |
| Mar ’25 | €19.50 | €18.91 -3.0% | 14.8% | €23.35 | €14.01 | n/a | 14 |
| Feb ’25 | €18.90 | €19.04 +0.8% | 13.8% | €23.00 | €14.72 | n/a | 15 |
| Jan ’25 | €21.00 | €17.91 -14.7% | 16.8% | €22.72 | €11.82 | n/a | 15 |
| Dec ’24 | €18.90 | €18.02 -4.6% | 16.8% | €23.35 | €12.14 | n/a | 15 |
| Nov ’24 | €16.30 | €18.97 +16.4% | 18.1% | €25.53 | €12.29 | €25.80 | 15 |
| Oct ’24 | €18.60 | €18.89 +1.6% | 17.7% | €24.89 | €12.90 | €24.60 | 15 |
| Sep ’24 | €16.40 | €18.89 +15.2% | 17.7% | €24.89 | €12.90 | €25.20 | 15 |
| Aug ’24 | €19.70 | €19.81 +0.6% | 13.1% | €24.24 | €16.16 | €28.60 | 15 |
| Jul ’24 | €21.00 | €20.42 -2.7% | 11.0% | €24.74 | €17.41 | €23.60 | 14 |
| Jun ’24 | €19.20 | €21.09 +9.8% | 10.5% | €25.26 | €17.78 | €18.00 | 13 |
| May ’24 | €15.70 | €20.37 +29.7% | 8.5% | €23.05 | €18.44 | €17.70 | 11 |
| Apr ’24 | n/a | €20.37 0% | 8.5% | €23.05 | €18.44 | €19.50 | 11 |
| Mar ’24 | n/a | €20.65 0% | 7.7% | €23.57 | €18.85 | €19.50 | 11 |
| Feb ’24 | n/a | €18.46 0% | 8.4% | €21.23 | €15.69 | €18.90 | 10 |
| Jan ’24 | n/a | €19.67 0% | 8.9% | €23.55 | €16.95 | €21.00 | 9 |
| Dec ’23 | n/a | €20.16 0% | 4.3% | €21.12 | €19.20 | €18.90 | 5 |
Analyst Forecast: Target price is lower than the current share price.